Cencora vs Bristol Myers Squibb
Side-by-side comparison of AI visibility scores, market position, and capabilities
Conshohocken PA pharmaceutical distribution (NYSE: COR, formerly AmerisourceBergen) at $316B+ revenue; Retina Consultants of America acquisition $4.4B (Jan 2025) expanding into specialty physician care competing with McKesson.
About
Cencora, Inc. (formerly AmerisourceBergen, rebranded August 2023) is a Conshohocken, Pennsylvania-based pharmaceutical distribution and healthcare services company — publicly traded on the New York Stock Exchange (NYSE: COR) as an S&P 500 Health Care component, ranked #10 on the 2024 Fortune 500 and #24 on the Global Fortune 500 — distributing brand-name, generic, and specialty pharmaceuticals, over-the-counter products, and home healthcare supplies to 110,000+ points of care across 11 countries through 46,000+ employees and $316+ billion in annual revenue. Cencora operates as one of the "Big Three" pharmaceutical wholesalers in the United States alongside McKesson and Cardinal Health, collectively supplying approximately 90%+ of the US pharmaceutical supply chain. The company distributes from 26 US pharmaceutical distribution centers and 1,300+ locations across 50+ countries. In January 2025, Cencora completed the acquisition of approximately 85% interest in Retina Consultants of America (RCA) — a leading management services organization for retina specialists — for $4.4 billion, advancing its strategy to expand from pharmaceutical distribution into specialty physician-administered treatments and the high-growth specialty pharmaceutical services market. Founded through the 2001 merger of AmeriSource Health Corporation and Bergen Brunswig Corporation, with predecessor companies tracing to the 1970s, Cencora adopted its current name (meaning "center, core, heart" in multiple languages) in 2023 to signal the brand's evolution beyond commodity distribution.
Princeton NJ biopharma (NYSE: BMY) at $48.3B 2024 revenue; Eliquis $13.3B, Opdivo $9.2B, Cobenfy schizophrenia launch; $23B acquisitions (Karuna+Mirati+RayzeBio) building next pipeline vs. Pfizer and Merck.
About
Bristol Myers Squibb (BMS) is a Princeton, New Jersey-based global biopharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: BMY) as an S&P 500 Healthcare component — discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular disease, immunology, and neuroscience through approximately 34,000 employees worldwide. In fiscal year 2024, BMS reported total revenue of $48.3 billion (+7% year-over-year), with its Growth Portfolio generating $22.6 billion (+17%), driven by blockbusters Eliquis ($13.3B anticoagulant), Opdivo ($9.2B immuno-oncology), and Revlimid ($5.8B multiple myeloma). New product revenue surged 77% to $3.6 billion, led by schizophrenia treatment Cobenfy (formerly KarXT), CAR-T therapy Breyanzi, anemia drug Reblozyl, and Opdualag checkpoint inhibitor combination. CEO Dr. Christopher Boerner assumed leadership in November 2023, accelerating BMS's pipeline expansion through three transformative acquisitions in 2024: Karuna Therapeutics ($14B, Cobenfy/KarXT for schizophrenia and Alzheimer's agitation), Mirati Therapeutics ($4.8B, KRAS-targeted oncology), and RayzeBio ($4.1B, radiopharmaceutical cancer therapy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.